Response to: 'Correspondence on 'A pilot study of tofacitinib for refractory Behçet's syndrome'' by Zou .
作者信息
Liu Jinjing, Zhao Chan, Zheng Wenjie
机构信息
Department of Rheumatology and Clinical Immunology, Key Laboratory of Rheumatology and Clinical Rheumatology, Ministry of Education, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Department of Ophthalmology, Peking Union Medical College Hospital, Key Laboratory of Ocular Fundus Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
出版信息
Ann Rheum Dis. 2023 Apr;82(4):e101. doi: 10.1136/annrheumdis-2020-219828. Epub 2021 Jan 25.
Abstract
摘要
相似文献
1
Response to: 'Correspondence on 'A pilot study of tofacitinib for refractory Behçet's syndrome'' by Zou .对邹的《托法替布治疗难治性白塞病的初步研究》的回复
Ann Rheum Dis. 2023 Apr;82(4):e101. doi: 10.1136/annrheumdis-2020-219828. Epub 2021 Jan 25.
2
Correspondence on 'A pilot study of tofacitinib for refractory Behçet's syndrome'.关于“托法替布治疗难治性白塞病的一项试点研究”的通信
Ann Rheum Dis. 2023 Apr;82(4):e100. doi: 10.1136/annrheumdis-2020-219810. Epub 2021 Jan 25.
3
A pilot study of tofacitinib for refractory Behçet's syndrome.托法替布治疗难治性白塞病的一项试点研究。
Ann Rheum Dis. 2020 Nov;79(11):1517-1520. doi: 10.1136/annrheumdis-2020-217307. Epub 2020 May 27.
4
Gastrointestinal: Refractory parastomal ulcers of Behcet's disease responsive to tofacitinib.胃肠道：对托法替布有反应的白塞病难治性造口旁溃疡。
J Gastroenterol Hepatol. 2023 Apr;38(4):485. doi: 10.1111/jgh.15997. Epub 2022 Oct 2.
5
Case report: Refractory intestinal Behçet's syndrome successfully treated with tofacitinib: A report of four cases.病例报告：托法替布治疗难治性肠道贝赫切特综合征四例报告。
Front Immunol. 2022 Sep 15;13:981502. doi: 10.3389/fimmu.2022.981502. eCollection 2022.
6
SER recommendations on treatment of refractory Behçet's syndrome.关于难治性贝赫切特综合征治疗的 SER 建议。
Reumatol Clin (Engl Ed). 2024 Apr;20(4):204-217. doi: 10.1016/j.reumae.2023.12.006. Epub 2024 Apr 12.
7
TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behçet's syndrome refractory to the conventional treatment modalities: a case series and review of the literature.肿瘤坏死因子-α拮抗剂和沙利度胺用于治疗对传统治疗方式难治的胃肠道白塞病：病例系列及文献综述
Clin Exp Rheumatol. 2015 Nov-Dec;33(6 Suppl 94):S129-37. Epub 2015 Oct 20.
8
Management of Behçet's syndrome.白塞病的管理
Curr Opin Rheumatol. 2016 Jan;28(1):45-50. doi: 10.1097/BOR.0000000000000231.
9
Multiple peripheral arterial and aortic aneurysms in Behcet's syndrome: a case report.白塞病合并多发外周动脉和主动脉瘤：一例报告
Clin Rheumatol. 2008 Feb;27(2):265-7. doi: 10.1007/s10067-007-0713-z. Epub 2007 Oct 11.
10
Baricitinib for the treatment of refractory vascular Behçet's disease.巴瑞替尼治疗难治性血管性白塞病。
Clin Immunol. 2023 May;250:109298. doi: 10.1016/j.clim.2023.109298. Epub 2023 Mar 24.
引用本文的文献
1
Rise of biologics in noninfectious uveitis: a retrospective cohort study from Nepal.生物制剂在非感染性葡萄膜炎中的应用增加：一项来自尼泊尔的回顾性队列研究。
Ann Med Surg (Lond). 2023 Apr 11;85(5):1486-1489. doi: 10.1097/MS9.0000000000000546. eCollection 2023 May.
2
Recent Insights into the Management of Behçet Syndrome.白塞病管理的最新见解
J Inflamm Res. 2021 Jul 20;14:3429-3441. doi: 10.2147/JIR.S285400. eCollection 2021.
Zotero 插件